Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Jeffrey M. Clarke"'
Autor:
Tianjiao Wang, Jean-Marc Navenot, Stavros Rafail, Cynthia Kurtis, Mark Carroll, Marian Van Kerckhoven, Sofie Van Rossom, Kelly Schats, Konstantinos Avraam, Robyn Broad, Karen Howe, Ashley Liddle, Amber Clayton, Ruoxi Wang, Laura Quinn, Joseph P. Sanderson, Cheryl McAlpine, Carly Carozza, Eric Pimpinella, Susan Hsu, Francine Brophy, Erica Elefant, Paige Bayer, Dennis Williams, Marcus O. Butler, Jeffrey M. Clarke, Justin F. Gainor, Ramaswamy Govindan, Victor Moreno, Melissa Johnson, Janet Tu, David S. Hong, George R. Blumenschein, Jr.
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 32, Iss 2, Pp 101265- (2024)
T cell receptor (TCR) T cell therapies target tumor antigens in a human leukocyte antigen (HLA)-restricted manner. Biomarker-defined therapies require validation of assays suitable for determination of patient eligibility. For clinical trials evaluat
Externí odkaz:
https://doaj.org/article/4a2c3428294d4a8f91abc7b22ea7bab3
Autor:
Anjali Gupta, Chioma Omeogu, Jessica Y. Islam, Ashwini Joshi, Dongyu Zhang, Dejana Braithwaite, Shama D. Karanth, Tina D. Tailor, Jeffrey M. Clarke, Tomi Akinyemiju
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Socioeconomic and racial disparities exist in access to care among patients with non-small cell lung cancer (NSCLC) in the United States. Immunotherapy is a widely established treatment modality for patients with advanced-stage NSCLC (aNSCLC
Externí odkaz:
https://doaj.org/article/25160e5fe08d435db56e66ee21ba0a2b
Autor:
Jeffrey M. Clarke, MD, Lin Gu, MS, Xiaofei F. Wang, PhD, Thomas E. Stinchcombe, MD, Marvaretta M. Stevenson, MD, Sundhar Ramalingam, MD, Afreen Shariff, MD, Jennifer Garst, MD, Andrew B. Nixon, PhD, Scott J. Antonia, MD, Jeffrey Crawford, MD, Neal E. Ready, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100337- (2022)
Introduction: Most patients with advanced NSCLC will experience disease progression and death within 2 years. Novel approaches are needed to improve outcomes. Methods: We conducted an open-label, nonrandomized, phase 2 trial in patients with treatmen
Externí odkaz:
https://doaj.org/article/4e8e10cbb46b4c6b9961babf7e012e44
Autor:
Erica Shen, Amanda E. D. Van Swearingen, Meghan J. Price, Ketan Bulsara, Roeland G. W. Verhaak, César Baëta, Brice D. Painter, Zachary J. Reitman, April K. S. Salama, Jeffrey M. Clarke, Carey K. Anders, Peter E. Fecci, C. Rory Goodwin, Kyle M. Walsh
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
As local disease control improves, the public health impact of brain metastases (BrM) continues to grow. Molecular features are frequently different between primary and metastatic tumors as a result of clonal evolution during neoplasm migration, sele
Externí odkaz:
https://doaj.org/article/561c32307db747c491a958063b9a8b4d
Autor:
David S. Hong, Brian A. Van Tine, Swethajit Biswas, Cheryl McAlpine, Melissa L. Johnson, Anthony J. Olszanski, Jeffrey M. Clarke, Dejka Araujo, George R. Blumenschein, Partow Kebriaei, Quan Lin, Alex J. Tipping, Joseph P. Sanderson, Ruoxi Wang, Trupti Trivedi, Thejo Annareddy, Jane Bai, Stavros Rafail, Amy Sun, Lilliam Fernandes, Jean-Marc Navenot, Frederic D. Bushman, John K. Everett, Derin Karadeniz, Robyn Broad, Martin Isabelle, Revashnee Naidoo, Natalie Bath, Gareth Betts, Zohar Wolchinsky, Dzmitry G. Batrakou, Erin Van Winkle, Erica Elefant, Armin Ghobadi, Amanda Cashen, Anne Grand’Maison, Philip McCarthy, Paula M. Fracasso, Elliot Norry, Dennis Williams, Mihaela Druta, David A. Liebner, Kunle Odunsi, Marcus O. Butler
Publikováno v:
Nature Medicine. 29:104-114
Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy. Afamitresgene autoleucel (afami-cel) is a human leukocyte antigen-restricted autologous T cell therapy targeting melanoma-associated antigen A4 (MAGE-A4), a cance
Autor:
John V. Heymach, Robin Cornelissen, Jonathan W. Goldman, Francois Lebel, Nishan Tchekmedyian, Gajanan Bhat, Szu-Yun Leu, Xiuning Le, Mark A. Socinski, Jeffrey M. Clarke, Marina Chiara Garassino
Publikováno v:
Journal of Clinical Oncology, 40(7), 710-718. American Society of Clinical Oncology
PURPOSE Insertion mutations in Erb-b2 receptor tyrosine kinase 2 gene ( ERBB2 or HER2) exon 20 occur in 2%-5% of non–small-cell lung cancers (NSCLCs) and function as an oncogenic driver. Poziotinib, a tyrosine kinase inhibitor, was evaluated in pre
Autor:
Kamran Mahmood, Parvathi Jampani, Jeffrey M. Clarke, Steven Wolf, Xiaofei Wang, Momen M. Wahidi, Coral X. Giovacchini, Michael Dorry, Scott L. Shofer, Jessica Shier, Greg Jones, Scott J. Antonia, Andrew B. Nixon
Publikováno v:
Chest.
Autor:
D. Ross Camidge, Martin Dunbar, Jyoti D. Patel, Jeffrey M. Clarke, Bruce A. Bach, Eddie Thara, Francisco Robert, Silpa Nuthalapati, Ebenezer A. Kio, Minh H. Dinh
Publikováno v:
Lung Cancer. 161:180-188
Objectives Both combinations of the PARP inhibitor veliparib plus platinum doublet chemotherapy (CT), and the programmed death receptor-1 (PD-1) inhibitor nivolumab plus CT have demonstrated encouraging efficacy for treatment of non-small cell lung c
Autor:
Yuan Wu, Chester Kao, Tian Zhang, Neal Ready, Michael B. Datto, Eric Powers, Jeffrey M. Clarke, John H. Strickler, Michelle F. Green
Publikováno v:
Clinical Lung Cancer. 22:500-509
Introduction A high tumor mutational burden (TMB) (≥10 mut/Mb) has been associated with improved clinical benefit in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) and is a tumor agnostic indication for pembroliz
Autor:
Monica H. Bodd, Susan C. Locke, Steve P. Wolf, Scott Antonia, Jeffrey Crawford, John Hartman, Kris W. Herring, Neal E. Ready, Thomas E. Stinchcombe, Jesse D. Troy, Chakita Williams, Jeffrey M. Clarke, Thomas W. LeBlanc
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 175
There are limited real-world data about patient-reported outcomes with immunotherapies (IO) in metastatic non-small cell lung cancer (mNSCLC). We describe patient-reported distress and clinical outcomes with IO-based treatments or cytotoxic chemother